SCO-267

Names

[ Name ]:
SCO-267

Biological Activity

[Description]:

SCO-267 is an allosteric GPR40 full agonist. SCO-267 can be used for the research of chronic diseases including diabetes[1].

[Related Catalog]:

Signaling Pathways >> GPCR/G Protein >> GPR40

Research Areas >> Metabolic Disease

[Target]

GPR40[1]

[In Vitro]

SCO-267 (CHO cells) activates the Gαq, Gαs, and Gα12/13 pathways and β-Arrestin Recruitment. SCO-267 is allosteric with fasiglifam and an endogenous ligand[1].

[In Vivo]

SCO-267 (1 or 10 mg/kg; p.o.) improves insulin sensitivity and exerts sustained glucose-lowering effect[1]. Animal Model: N-STZ rats[1] Dosage: 1 or 10 mg/kg Administration: P.o.; Result: Improved insulin sensitivity and exerted sustained glucose-lowering effect.

[References]

[1]. Koyama R, et al. Chronic Exposure to SCO-267, an Allosteric GPR40 Full Agonist, Is Effective in Improving Glycemic Control in Rats. Mol Pharmacol. 2021 Apr;99(4):286-293.

Chemical & Physical Properties

[ Molecular Formula ]:
C₃₆H₄₆N₄O₅

[ Molecular Weight ]:
614.77

SCO-267

Names

Biological Activity

Chemical & Physical Properties

Related Compounds